Osteoporosis growth hormone

Growth hormone (GH) and IGF-1 play important roles in bone turnover and remodeling, with multiple effects on other tissues. Their serum concentrations decline with age and frequently are decreased in osteoporosis. Growth hormone injections have been found to increase or cause no change in BMD in patients with osteoporosis and normal GH concentrations, and patients with GH deficiency. Short-... 

Human growth hormone, used as a human pharmaceutical, is approved for only one indication in the United States, treatment of growth failure owing to hGH deficiency, a condition known as pituitary dwarfism. However, clinical trials are under way to test its efficacy in Turner s syndrome, bums, wound healing, cachexia, osteoporosis, constitutional growth delay, aging, malnutrition, and obesity. 

Established indications for somatropin (growth hormone) include growth hormone deficiency in children, Turner s syndrome, Noonan s syndrome, and renal insufficiency in children. Other well-studied indications include idiopathic short stature, adult growth hormone deficiency, osteoporosis, and catabolic states associated with acute and chronic illness and injury. Body composition, respiratory muscle function, physical strength, and height improved in a 12-month trial of somatropin in 54 children with Prader-Willi syndrome (1). 

Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis a randomised placebo-con-trolled trial. J Bone Mineral Res 2003 18 393 105. 

M2. Marcus, R., Recombinant human growth hormone as potential therapy for osteoporosis. Baill. Clin. Endocrinol. Metab. 12, 251-260 (1998). 

TransPharma-Medical, an Israeli-based pharmaceutical company, is investigating the transdermal delivery of human parathyroid hormone fragment for the treatment of osteoporosis in addition to the delivery of human growth hormone [41], This technology utilizes a 1-cm2 patch that creates small channels or holes in the stratum... 

Geusens PP, Boonen S. Osteoporosis and the growth hormone-insulin-hke growth factor axis. Horm Res 2002 58(Suppl 3) 49—55. 

Effect on Electrolytes. The administration of human growth hormone raises the intracellular levels of electrolytes, leads to a loss of bone calcium, and reduces urinary levels of phosphorus, potassium, and sodium. The increase in intracellular electrolytes may result from an increase in the cellular mass. Mobilization of bone calcium leads to osteoporosis in acromegaly and calciuria. Two explanations offered for this are (1) increased glomerular filtration combined with inhibition of tubular reabsorption, and (2) stimulation of parathyroid secretion. 

Kruse, H. P. and Kuhlencordt, F. (1975) On an attempt to treat primary and secondary osteoporosis with human growth hormone. Hormone metabol. Res., 7, 488. 

---